Tumor Biology

, Volume 36, Issue 10, pp 7493–7499 | Cite as

Lysosome-associated protein transmembrane-4β-35 is a novel independent prognostic factor in small cell lung cancer

  • Man Qiao
  • Guohua Hu
Research Article


The lysosome-associated protein transmembrane-4β-35 (LAPTM4B-35) protein has been indicated to be involved in solid tumors, while its role in small cell lung cancer (SCLC) remains unknown. The aim of this study is to investigate the LAPTM4B-35 protein expression and its clinical and prognostic role in SCLC patients. A total of 88 SCLC patients who underwent radical surgery between 2002 and 2010 were enrolled in the study. The level of messenger RNA (mRNA) and protein was detected from the fresh paired tumor specimens and adjacent normal tissues. The clinicopathological and survival data were collected. And the relationship between LAPTM4B-35 and clinicopathological features was analyzed. The prognostic value of LAPTM4B-35 for SCLC was investigated by univariate and multivariate analyses. The LAPTM4B-35 was overexpressed significantly in SCLC cancer tissues. The elevated protein expression was correlated strongly with clinical stage (p = 0.012) and tumor recurrence (p = 0.023). The 5-year overall survival and disease-free survival (DFS) were significantly worse in the patients with high LAPTM4B-35 level. Multivariate Cox analysis indicated that high LAPTM4B-35 expression was an independent prognostic factor for overall survival (OS) and DFS (p = 0.017 vs p = 0.011). LAPTM4B-35 overexpression was an independent factor in SCLC prognosis, which may be considered a potential useful marker in defining the SCLC prognosis.


Small cell lung cancer LAPTM4B-35 Prognosis 



We thank Gomes S for critical reading of the manuscript.

Conflicts of interest



  1. 1.
    Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015;65:5–29.CrossRefPubMedGoogle Scholar
  2. 2.
    Govindan R, Page N, Morgensztern D, Read W, Tierney R, Vlahiotis A, et al. Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database. J Clin Oncol. 2006;24:4539–44.CrossRefPubMedGoogle Scholar
  3. 3.
    Tartarone A, Lerose R, Ardito R, Troiani L, Tedesco B, Bozza G, et al. Long-term survival in small cell lung cancer: a case report and review of the literature. Future Oncol. 2014;10:523–8.CrossRefPubMedGoogle Scholar
  4. 4.
    Kalemkerian GP. Advances in pharmacotherapy of small cell lung cancer. Expert Opin Pharmacother. 2014;15:2385–96.CrossRefPubMedGoogle Scholar
  5. 5.
    Pillai RN, Owonikoko TK. Small cell lung cancer: therapies and targets. Semin Oncol. 2014;41:133–42.CrossRefPubMedGoogle Scholar
  6. 6.
    Osterlind K, Andersen PK. Prognostic factors in small cell lung cancer: multivariate model based on 778 patients treated with chemotherapy with or without irradiation. Cancer Res. 1986;46:4189–94.PubMedGoogle Scholar
  7. 7.
    Paesmans M, Sculier JP, Lecomte J, Thiriaux J, Libert P, Sergysels R, et al. Prognostic factors for patients with small cell lung carcinoma: analysis of a series of 763 patients included in 4 consecutive prospective trials with a minimum follow-up of 5 years. Cancer. 2000;89:523–33.CrossRefPubMedGoogle Scholar
  8. 8.
    Li J, Dai CH, Chen P, Wu JN, Bao QL, Qiu H, et al. Survival and prognostic factors in small cell lung cancer. Med Oncol. 2010;27:73–81.CrossRefPubMedGoogle Scholar
  9. 9.
    Bremnes RM, Sundstrom S, Aasebo U, Kaasa S, Hatlevoll R, Aamdal S. The value of prognostic factors in small cell lung cancer: results from a randomised multicenter study with minimum 5 year follow-up. Lung Cancer. 2003;39:303–13.CrossRefPubMedGoogle Scholar
  10. 10.
    Ustuner Z, Saip P, Yasasever V, Vural B, Yazar A, Bal C, et al. Prognostic and predictive value of vascular endothelial growth factor and its soluble receptors, VEGFR-1 and VEGFR-2 levels in the sera of small cell lung cancer patients. Med Oncol. 2008;25:394–9.CrossRefPubMedGoogle Scholar
  11. 11.
    Wang X, Jiang R, Li K. Prognostic significance of pretreatment laboratory parameters in combined small-cell lung cancer. Cell Biochem Biophys. 2014;69:633–40.CrossRefPubMedGoogle Scholar
  12. 12.
    Wu C, Li F, Jiao SC. Prognostic factors for survival of patients with extensive stage small cell lung cancer—a retrospective single institution analysis. Asian Pac J Cancer Prev. 2012;13:4959–62.CrossRefPubMedGoogle Scholar
  13. 13.
    Liu XR, Zhou RL, Zhang QY, Zhang Y, Jin YY, Lin M, et al. Structure analysis and expressions of a novel tetratransmembrane protein, lysosoma-associated protein transmembrane 4 beta associated with hepatocellular carcinoma. World J Gastroenterol. 2004;10:1555–9.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Shao GZ, Zhou RL, Zhang QY, Zhang Y, Liu JJ, Rui JA, et al. Molecular cloning and characterization of LAPTM4B, a novel gene upregulated in hepatocellular carcinoma. Oncogene. 2003;22:5060–9.CrossRefPubMedGoogle Scholar
  15. 15.
    Liu L, Xu X, Jing L, Zhou G, Cao Z, Han Y, et al. Lysosomal-associated protein transmembrane 4 beta-35 overexpression is a novel independent prognostic marker for gastric carcinoma. PLoS One. 2015;10:e0118026.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Zhang H, Wei Q, Liu R, Qi S, Liang P, Qi C, et al. Overexpression of LAPTM4B-35: a novel marker of poor prognosis of prostate cancer. PLoS One. 2014;9:e91069.CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Zhang G, Liang Y, Huang Y, Chen Y, Zhou R. Elevated lysosome-associated protein transmembrane-4beta-35 is an independent prognostic marker in pancreatic carcinoma. J Int Med Res. 2012;40:1275–83.CrossRefPubMedGoogle Scholar
  18. 18.
    Kang Y, Yin M, Jiang W, Zhang H, Xia B, Xue Y, et al. Overexpression of LAPTM4B-35 is associated with poor prognosis in colorectal carcinoma. Am J Surg. 2012;204:677–83.CrossRefPubMedGoogle Scholar
  19. 19.
    Tang H, Tian H, Yue W, Li L, Li S, Gao C, et al. Overexpression of LAPTM4B is correlated with tumor angiogenesis and poor prognosis in non-small cell lung cancer. Med Oncol. 2014;31:974.CrossRefPubMedGoogle Scholar
  20. 20.
    van Meerbeeck JP, Fennell DA, De Ruysscher DK. Small-cell lung cancer. Lancet. 2011;378:1741–55.CrossRefPubMedGoogle Scholar
  21. 21.
    Adelstein DJ, Tomashefski Jr JF, Snow NJ, Horrigan TP, Hines JD. Mixed small cell and non-small cell lung cancer. Chest. 1986;89:699–704.CrossRefPubMedGoogle Scholar
  22. 22.
    Babakoohi S, Fu P, Yang M, Linden PA, Dowlati A. Combined SCLC clinical and pathologic characteristics. Clin Lung Cancer. 2013;14:113–9.CrossRefPubMedGoogle Scholar
  23. 23.
    Mangum MD, Greco FA, Hainsworth JD, Hande KR, Johnson DH. Combined small-cell and non-small-cell lung cancer. J Clin Oncol. 1989;7:607–12.CrossRefPubMedGoogle Scholar
  24. 24.
    Nicholson SA, Beasley MB, Brambilla E, Hasleton PS, Colby TV, Sheppard MN, et al. Small cell lung carcinoma (SCLC): a clinicopathologic study of 100 cases with surgical specimens. Am J Surg Pathol. 2002;26:1184–97.CrossRefPubMedGoogle Scholar
  25. 25.
    Xiao M, Jia S, Wang H, Wang J, Huang Y, Li Z. Overexpression of LAPTM4B: an independent prognostic marker in breast cancer. J Cancer Res Clin Oncol. 2013;139:661–7.CrossRefPubMedGoogle Scholar
  26. 26.
    Yin M, Li C, Li X, Lou G, Miao B, Liu X, et al. Over-expression of LAPTM4B is associated with poor prognosis and chemotherapy resistance in stages III and IV epithelial ovarian cancer. J Surg Oncol. 2011;104:29–36.CrossRefPubMedGoogle Scholar
  27. 27.
    Zhou L, He XD, Chen J, Cui QC, Qu Q, Rui JA, et al. Overexpression of LAPTM4B-35 closely correlated with clinicopathological features and post-resectional survival of gallbladder carcinoma. Eur J Cancer. 2007;43:809–15.CrossRefPubMedGoogle Scholar
  28. 28.
    Meng F, Luo C, Hu Y, Yin M, Lin M, Lou G, et al. Overexpression of LAPTM4B-35 in cervical carcinoma: a clinicopathologic study. Int J Gynecol Pathol. 2010;29:587–93.CrossRefPubMedGoogle Scholar
  29. 29.
    Yang H, Xiong F, Wei X, Yang Y, McNutt MA, Zhou R. Overexpression of LAPTM4B-35 promotes growth and metastasis of hepatocellular carcinoma in vitro and in vivo. Cancer Lett. 2010;294:236–44.CrossRefPubMedGoogle Scholar
  30. 30.
    Zhou L, He XD, Yu JC, Zhou RL, Yang H, Qu Q, et al. Overexpression of LAPTM4B promotes growth of gallbladder carcinoma cells in vitro. Am J Surg. 2010;199:515–21.CrossRefPubMedGoogle Scholar
  31. 31.
    Yang H, Zhai G, Ji X, Xiong F, Su J, McNutt MA. LAPTM4B allele *2 is a marker of poor prognosis following hepatic tumor resection for hepatocellular carcinoma. PLoS One. 2012;7:e34984.CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    Li Y, Zhang Q, Tian R, Wang Q, Zhao JJ, Iglehart JD, et al. Lysosomal transmembrane protein LAPTM4B promotes autophagy and tolerance to metabolic stress in cancer cells. Cancer Res. 2011;71:7481–9.CrossRefPubMedPubMedCentralGoogle Scholar
  33. 33.
    Li L, Wei XH, Pan YP, Li HC, Yang H, He QH, et al. LAPTM4B: a novel cancer-associated gene motivates multidrug resistance through efflux and activating PI3K/AKT signaling. Oncogene. 2010;29:5785–95.CrossRefPubMedGoogle Scholar
  34. 34.
    Li Y, Zou L, Li Q, Haibe-Kains B, Tian R, Desmedt C, et al. Amplification of LAPTM4B and YWHAZ contributes to chemotherapy resistance and recurrence of breast cancer. Nat Med. 2010;16:214–8.CrossRefPubMedPubMedCentralGoogle Scholar
  35. 35.
    Zhou L, He XD, Yu JC, Zhou RL, Shan Y, Rui JA. Overexpression of LAPTM4B-35 attenuates epirubucin-induced apoptosis of gallbladder carcinoma GBC-SD cells. Surgery. 2011;150:25–31.CrossRefPubMedGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2015

Authors and Affiliations

  1. 1.Department of Respiratory MedicineTianjin Hospital of ITCWM, Nankai HospitalTianjinChina

Personalised recommendations